Lisata Therapeutics is a biopharmaceutical company providing platform technologies for solid tumors and other major diseases treatment. It offers clinical-stage diagnostics and therapy programs for patients with diabetic kidney disease, Buerger’s disease, coronary microvascular dysfunction, first-line metastatic pancreatic ductal adenocarcinoma, etc. The company also conducts oncology and ischemic disease clinical trials. Lisata Therapeutics was created as a result of a merger between Caladrius Biosciences and Cend Therapeutics.